Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Recommendation - Pharmacoeconomic Report. 2014 Authors' conclusions At the submitted price of XXXXXX, lurasidone (XXXXXX per year) is less expensive than aripiprazole ($1,509 to $1,746 per year) and ziprasidone ($1,448 per year). Therefore, lurasidone would generate modest cost savings for public plans if it were used instead of aripiprazole or ziprasidone. By contrast, lurasidone is more expensive than quetiapine ($352 to $705) and risperidone ($443 to $665), regardless of dose. Therefore, lurasidone would incur additional costs to public plans if it were used instead of quetiapine or risperidone. Whether lurasidone is more or less expensive than other AAPs (olanzapine, risperidone ODT, quetiapine XR, paliperidone) depends on the dose considered and prices within individual public plans. Indexing Status Subject indexing assigned by CRD MeSH Isoindoles; Schizophrenias; Thiazoles Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000813 Date abstract record published 16/07/2014 |